Recent Finacing
Recent Raise
Notch Therapeutics develops homogeneous, universally compatible iPSC-derived T cell and NK cell therapies using an Engineered Thymic Niche (ETN) platform, with an integrated immune-cell generation/editing pipeline and Allogene partnership.
